Sakar Healthcare Limited (SAKAR.NS)
INR 258.29
(6.94%)
INR 258.29
(6.94%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 495.5 Million INR | 159.2% |
| 2022 | 191.16 Million INR | -7.37% |
| 2021 | 206.37 Million INR | 36.44% |
| 2020 | 151.25 Million INR | 11.18% |
| 2019 | 136.04 Million INR | 24.36% |
| 2018 | 109.39 Million INR | 33.03% |
| 2017 | 82.23 Million INR | 70.56% |
| 2016 | 48.21 Million INR | 68.53% |
| 2015 | 28.6 Million INR | -46.8% |
| 2014 | 53.76 Million INR | -6.11% |
| 2013 | 57.26 Million INR | 3.0% |
| 2012 | 55.59 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 63.82 Million INR | 13.13% |
| 2024 Q1 | 56.41 Million INR | -7.57% |
| 2023 Q1 | 45.07 Million INR | -25.34% |
| 2023 Q2 | 57.96 Million INR | 28.6% |
| 2023 FY | 207.92 Million INR | 8.77% |
| 2023 Q4 | 61.03 Million INR | 33.71% |
| 2023 Q3 | 45.64 Million INR | -21.25% |
| 2022 Q2 | 54.3 Million INR | 23.77% |
| 2022 Q4 | 60.36 Million INR | -7.94% |
| 2022 FY | 191.16 Million INR | -7.37% |
| 2022 Q1 | 43.87 Million INR | -25.71% |
| 2022 Q3 | 65.57 Million INR | 20.76% |
| 2021 Q2 | 54.14 Million INR | 25.82% |
| 2021 Q1 | 43.03 Million INR | 90.33% |
| 2021 FY | 206.37 Million INR | 36.44% |
| 2021 Q4 | 59.06 Million INR | 46.4% |
| 2021 Q3 | 40.34 Million INR | -25.49% |
| 2020 Q1 | 36.31 Million INR | 34.44% |
| 2020 FY | 151.25 Million INR | 11.18% |
| 2020 Q4 | 22.6 Million INR | -18.72% |
| 2020 Q3 | 27.81 Million INR | -52.69% |
| 2020 Q2 | 58.79 Million INR | 61.93% |
| 2019 Q3 | 32.9 Million INR | -18.13% |
| 2019 Q1 | 24.58 Million INR | -24.92% |
| 2019 FY | 136.04 Million INR | 24.36% |
| 2019 Q2 | 40.19 Million INR | 63.48% |
| 2019 Q4 | 27 Million INR | -17.93% |
| 2018 Q3 | 34.05 Million INR | 18.29% |
| 2018 Q4 | 32.74 Million INR | -3.82% |
| 2018 FY | 109.39 Million INR | 33.03% |
| 2018 Q1 | 13.81 Million INR | 0.0% |
| 2018 Q2 | 28.78 Million INR | 108.43% |
| 2017 FY | 82.23 Million INR | 70.56% |
| 2016 FY | 48.21 Million INR | 68.53% |
| 2016 Q4 | 27.32 Million INR | 0.0% |
| 2015 Q2 | 22.53 Million INR | 0.0% |
| 2015 Q3 | 6.43 Million INR | -71.44% |
| 2015 Q4 | 20.62 Million INR | 220.48% |
| 2015 FY | 28.6 Million INR | -46.8% |
| 2015 Q1 | 22.53 Million INR | 404.03% |
| 2014 FY | 53.76 Million INR | -6.11% |
| 2014 Q4 | 4.47 Million INR | 0.0% |
| 2013 FY | 57.26 Million INR | 3.0% |
| 2012 FY | 55.59 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 91.395% |
| Hester Biosciences Limited | 364.77 Million INR | -35.841% |
| Aarti Drugs Limited | 7.14 Billion INR | 93.069% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 84.16% |
| Albert David Limited | 1.33 Billion INR | 62.868% |
| Alembic Limited | 767.77 Million INR | 35.462% |
| Alkem Laboratories Limited | 19.46 Billion INR | 97.454% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | -108.493% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | -2298.848% |
| Brooks Laboratories Limited | -72.25 Million INR | 785.802% |
| Eris Lifesciences Limited | 5.18 Billion INR | 90.437% |
| FDC Limited | 3.03 Billion INR | 83.667% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 94.482% |
| Gufic Biosciences Limited | 2.89 Billion INR | 82.877% |
| Hikal Limited | 1.49 Billion INR | 66.838% |
| Ind-Swift Limited | 1.22 Billion INR | 59.582% |
| Innova Captab Limited | 2.53 Billion INR | 80.441% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | 89.974% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | -131.502% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 90.451% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | 74.007% |
| Lupin Limited | 27.75 Billion INR | 98.215% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -1704.596% |
| Medico Remedies Limited | 277.11 Million INR | -78.807% |
| Morepen Laboratories Limited | 4.17 Billion INR | 88.128% |
| Nectar Lifesciences Limited | 3.89 Billion INR | 87.264% |
| Orchid Pharma Limited | 2.36 Billion INR | 79.014% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 82.214% |
| RPG Life Sciences Limited | 2.29 Billion INR | 78.384% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -138.167% |
| Sigachi Industries Limited | 1.47 Billion INR | 66.381% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 112.861% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 89.246% |
| Themis Medicare Limited | 1.3 Billion INR | 61.975% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Vaishali Pharma Limited | 6.29 Million INR | -7772.672% |
| Wanbury Limited | 1.7 Billion INR | 70.976% |
| Windlas Biotech Limited | 1.29 Billion INR | 61.852% |
| ZIM Laboratories Limited | 1.09 Billion INR | 54.877% |
| Ind-Swift Laboratories Limited | 2 Billion INR | 75.336% |
| Ipca Laboratories Limited | 29.59 Billion INR | 98.326% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 99.525% |
| Venus Remedies Limited | 534.65 Million INR | 7.322% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 99.526% |
| Divi's Laboratories Limited | 18.31 Billion INR | 97.294% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | 88.925% |
| Mankind Pharma Limited | 40.86 Billion INR | 98.788% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Laurus Labs Limited | 3.94 Billion INR | 87.451% |
| Neuland Laboratories Limited | 5.31 Billion INR | 90.683% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 93.43% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 92.38% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 98.908% |
| Amrutanjan Health Care Limited | 621.02 Million INR | 20.212% |
| Wockhardt Limited | 140 Million INR | -253.933% |
| Bal Pharma Limited | 214.56 Million INR | -130.931% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 99.268% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 59.748% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | 10.168% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 93.142% |
| Shilpa Medicare Limited | 3.76 Billion INR | 86.827% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 19.67 Billion INR | 97.482% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | -17403.937% |
| Granules India Limited | 6.52 Billion INR | 92.41% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -98.798% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 98.044% |
| NATCO Pharma Limited | 25.96 Billion INR | 98.091% |
| Suven Life Sciences Limited | -1.22 Billion INR | 140.422% |
| Krebs Biochemicals & Industries Limited | - INR | -Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 90.518% |
| Indoco Remedies Limited | 1.52 Billion INR | 67.495% |
| Alpa Laboratories Limited | 61.51 Million INR | -705.504% |
| Lasa Supergenerics Limited | -458 Million INR | 208.188% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 112.041% |